WilmerHale Advises General Catalyst in Capital Rx's Series C Funding

WilmerHale Advises General Catalyst in Capital Rx's Series C Funding

Client News

On June 13, 2022, Capital Rx, a health technology company, announced that it has secured $106M in Series C funding. General Catalyst, a venture capital firm specializing in early-stage and growth equity investments, was among the investors that contributed to the round of funding. The funding will be used to advance Capital Rx's mission of modernizing prescription and healthcare infrastructure to increase operational efficiency and improve patient care.

The WilmerHale team advising General Catalyst was led by Jason Kropp and Jahnvi Desai.